Sclerosis News and Research

RSS

XenoPort first quarter revenues increase to $10.4 million

XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.

3 May 2012

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.

2 May 2012

Antibody that neutralizes enzyme Kallikrein 6 staves off MS

Researchers studying multiple sclerosis(MS) have long been looking for the specific molecules in the body that cause lesions in myelin, the fatty, insulating cells that sheathe the nerves.

30 Apr 2012

Kadimastem, Merck Serono enter agreement for MS drug-screening platform

Kadimastem, an Israeli Biotechnology company that develops human pluripotent stem cell-related products, today announced the signing of a five year framework agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

30 Apr 2012

Cedars-Sinai scientist receives ALS Association Golden West Chapter Commitment to a Cure Award

Robert H. Baloh, MD, PhD, director of Cedars-Sinai Medical Center's Neuromuscular Division, has received the ALS Association Golden West Chapter Commitment to a Cure Award.

30 Apr 2012

Researchers define structure of key part of human obesity receptor

Medical researchers at the University of Sheffield have defined the structure of a key part of the human obesity receptor- an essential factor in the regulation of body fat- which could help provide new treatments for the complications of obesity and anorexia.

27 Apr 2012

Rochester researcher to continue MS study

A Rochester, New York, researcher will receive a $263,622 grant to continue his study of injury to brain cell connections (synapses) in multiple sclerosis (MS) through the American Brain Foundation (formerly the American Academy of Neurology Foundation) and the National Multiple Sclerosis Society Clinician-Scientist Development Award.

27 Apr 2012

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.

27 Apr 2012

Novartis receives FDA approval for Afinitor to treat renal angiomyolipomas caused by TSC

The U.S. Food and Drug Administration approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex.

27 Apr 2012

Iowa House approves mental health reforms

The bill would replace the county-by-county system in Iowa. Also in state legislative news, N.H. gubernatorial candidate opposes health care compact proposal and California lawmaker seeks cap on consumers' prescription drug expenses.

26 Apr 2012

Elan first quarter total revenue increases 17% to $288.4 million

Elan Corporation, plc, today reported its first quarter 2012 financial results.

26 Apr 2012

NYU Langone expands MS Comprehensive Care Center

NYU Langone's Multiple Sclerosis (MS) Comprehensive Care Center recently opened the doors to a new clinical practice - the first to occupy NYU Langone Medical Center's new, nearly 300,000-square-foot Ambulatory Care Center located at 240 East 38th Street at Second Avenue in Manhattan.

26 Apr 2012

Vitamin D supplementation in winter can help lower blood pressure in hypertensive patients

A new study, presented at the European Society of Hypertension meeting in London, shows that vitamin D supplementation in winter can help lower blood pressure in patients with hypertension.

25 Apr 2012

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Today Biogen Idec announced that detailed positive data from CONFIRM, the second Phase 3 clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS), will be presented in three platform presentations at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans.

25 Apr 2012

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.

23 Apr 2012

Two new studies analyze treatment decisions in late-stage ALS patients

Two new studies analyzing treatment decisions in late-stage amyotrophic lateral sclerosis (ALS) patients shed light onto treatments aimed to extend the duration and quality of life in this progressively debilitating neuromuscular disorder.

21 Apr 2012

Kessler Foundation scientist to develop predictive model of unemployment in MS

Lauren Strober, PhD, has been awarded a five-year federal grant for $554,000 to study factors relating to unemployment in people with multiple sclerosis (MS). Dr. Strober is a research scientist at Kessler Foundation, a major center for cognitive research and training in multiple sclerosis and a leader in the field of disability employment.

20 Apr 2012

Interferon beta-1a shows promise against MS

People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program at the American Academy of Neurology's 64th Annual Meeting in New Orleans, April 21 to April 28, 2012.

20 Apr 2012

Clinical study to evaluate high-dose vitamin D supplements for MS

Doctors at several centers across the U.S. are recruiting people who have multiple sclerosis (MS) to determine the effectiveness of high-dose vitamin D supplements for reducing MS disease activity.

20 Apr 2012

SBU to advance research and clinical care at National Pediatric MS Center

Stony Brook University has received a $2.5 million gift from Robert and Lisa Lourie to advance research and clinical care at the National Pediatric Multiple Sclerosis (MS) Center at Stony Brook Long Island Children's Hospital and to establish a new state-of-the-art imaging center at Stony Brook Medicine.

19 Apr 2012